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Abstract
Objectives: Studies in humans and rodents suggest that metformin, a medicine typically used to treat type 2 diabetes, may
have beneficial effects on memory. We sought to determine whether metformin improved spatial or verbal memory in
children with autism spectrum disorder (ASD) and overweight associated with atypical antipsychotic use.
Methods:We studied the effects of metformin (Riomet) concentrate on spatial and verbal memory in 51 youth with ASD,
ages 6 through 17 years, whowere taking atypical antipsychoticmedications, had gained significantweight, andwere enrolled
in a trial of metformin for weight management. Phase 1 was a 16-week, randomized, double-blind, placebo-controlled,
parallel-group comparison ofmetformin (500–850mggiven twice a day) versus placebo.During Phase 2, all participants took
open-label metformin fromweek 17 through week 32.We assessed spatial and verbal memory using the Neuropsychological
Assessment 2nd Edition (NEPSY–II) and a modified children’s verbal learning task.
Results:No measures differed between participants randomized to metformin versus placebo, at either 16 or 32 weeks, after
adjustment for multiple comparisons. Sixteen-week change in memory for spatial location on the NEPSY–II was nominally
better among participants randomized to placebo. However, patterns of treatment response across all measures revealed no
systematic differences in performance, suggesting thatmetformin had no effect on spatial or verbal memory in these children.
Conclusions:Although further study is needed to support these null effects, the overall impression is that metformin does not
affect memory in overweight youth with ASD who were taking atypical antipsychotic medications.
Keywords: metformin, autism spectrum disorder, overweight, atypical antipsychotic, memory
Introduction
Some evidence suggests that metformin, a medication typi-cally used to treat type 2 diabetes (T2D), could have beneficial
cognitive effects. This could be due to either neuroprotection from
the negative effects of T2D itself or due to independent effects
of metformin on brain function, potentially through enhanced
neurogenesis.
The suspicion that metformin might be neuroprotective first
arose from the observation of inflated risk of Alzheimer’s disease
(AD) among patients with T2D, leading some to dub the co-
occurring deterioration as ‘‘type 3 diabetes’’ (Steen et al. 2005; de
la Monte and Wands 2008). In a large observational cohort
(N = 127,209) of older adults (‡50 years), T2D was strongly asso-
ciated with AD, but the hazard for dementia was markedly lower
among adults taking metformin, sulfonylureas, or a combination of
the two (Hsu, Wahlquist, Lee, and Tsai 2011). Guo et al. (2014)
randomized 58 adults, 40–65 years of age with depression and T2D,
to placebo (n= 29) or metformin (n= 29). After 12 weeks, the
metformin group had significant improvement on the Wechsler
Memory Scales-Revised and on two depression rating scales. Im-
provements in memory and depression were inversely correlated,
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making it difficult to assess whether the primary benefit of met-
formin was on memory, mood, or both.
A number of in vitro and animal models of T2D have studied
metformin’s effect on markers of neurodegeneration or neuropro-
tection. Chen et al. (2009) found that metformin, when administered
alone, significantly increased b amyloid (Ab) peptides in cultured
mouse neuroblastoma cells and primary neurons, but that insulin and
metformin, when administered together, reduced Ab concentrations.
Using a different approach, Gupta, Bisht, and Day (2011) exposed
mouse neuroblastoma cells to exogenous insulin to produce neuronal
insulin resistance, leading to classical AD neuropathological changes.
However, exposure to metformin significantly reversed the insulin
resistance and reduced the molecular AD-like neuropathological cell
changes. Correia et al. (2008) administered 4 weeks of metformin to
Goto Kakizaki rats, a substrain that develops diabetes early in life.
Metformin exerted the expected antihyperglycemic effects and it was
also associated with decreases in several measures of oxidative stress,
suggesting the potential for neuroprotective effects.
In vivo studies of metformin’s impact on memory function in
animal models of T2D have also yielded suggestive but mixed re-
sults. Pintana et al. (2012) compared the effects of high-fat diet
(HFD), which is commonly used to model T2D, on memory and
exploratory behavior, as well as metabolic variables, in Wistar rats.
Twelve weeks of HFD caused significant increases in body weight,
plasma insulin, plasma cortisol, and homeostatic model assessment
(HOMA) index. Three weeks of subsequent metformin significantly
reduced all of these metabolic indices. Compared with normal-diet
rats, the HFD rats took significantly longer to locate a platform in a
Morris water maze test and spent less time in the target quadrant,
reflecting worse learning or memory. Metformin enhanced both in-
dices of learning, but only in the HFD rats. In contrast, Lennox et al.
(2014) studied the effects of 20 days of treatment with glucagon-like
peptide-1 (GLP-1) agonist and metformin in HFD mice. GLP-1
agonist alone and GLP-1 agonist + metformin improved an index of
recognition memory, but metformin monotherapy had no effect.
Metformin has also been studied as a potential neuroprotective
agent in animal models of other brain disorders. For example, in a
mouse model of Huntington’s disease, Ma et al. (2006) found that
2mg/kg, but not 5mg/kg of metformin, starting at 5 weeks of age,
led to increased lifespan (27% increase) and decreased hindlimb
clasping (a sign of ataxia) in male mice but not in female mice.
Venna et al. (2014) employed a middle cerebral artery occlusion
mouse model of ischemic stroke. They gave metformin for 3
weeks and found improved recovery of motor function that was
paralleled by enhanced development of new blood vessels up to
30 days later.
These results also raise the possibility that metformin has pro-
cognitive effects that are independent of protection from T2D or other
brain insult.Wang et al. (2012) found thatmetformin promotedmouse
neurogenesis in vitro in cultured neuronal stem cells and in vivo in the
hippocampus. They then testedwhethermetformin improvedmemory
performance in the Morris water maze, a common test of spatial
learning and memory. Mice that received 38 days of metformin in-
jections were no better at learning the initial location of a platform in
the maze compared with mice that received saline injections; how-
ever, the metformin-treated mice surpassed controls in learning a new
location when the platform was moved. This report preceded onset of
a clinical trial of metformin in children with autism spectrum disorder
(ASD; Anagnostou et al. 2016) and prompted us to add measures of
spatial memory to the weight reduction study.
For this study, we aimed to evaluate the impact of metformin on
spatial and verbal memory as an ancillary study within a random-
ized controlled trial of metformin for youth with ASD, whose
overweight was associated with prescription of atypical antipsy-
chotics. Our primary hypothesis was that individuals prescribed
metformin, in comparison to those in the placebo arm, would
demonstrate a beneficial effect on spatial memory. We chose a
spatial memory task in an attempt to parallel the Morris water maze
results (Wang et al. 2012). We included a verbal memory test as
well to cover the possibility that any effect on memory may be
broader than just spatial. Second, if metformin improved memory
in the short term, we predicted ‘‘catch-up’’ in placebo participants
during Phase 2, when all participants received metformin.
Methods
Design and participants
The background, methods, and primary outcomes (i.e., weight
indices, side effects, and behavioral changes) of the main trial were
described previously (Anagnostou et al. 2016). Participants were
recruited from four academic sites participating in the Autism
Speaks Autism Treatment Network (ASATN) (Bloorview Re-
search Institute, Ohio State University, University of Pittsburgh,
and Vanderbilt University Medical Center). This study was ap-
proved by the Institutional Review Boards at the four participating
study sites and the ASATN clinical and data-coordinating centers.
Caregivers and legal guardians signed informed consent documents
and if cognitively able to do so, participating youth assented to
study participation.
Intelligence Quotient (IQ) was assessed during the screen visit
using the Stanford–Binet Intelligence Scale V (Roid 2003) or
Mullen Scales of Early Learning AGS Edition (Mullen 1989). Most
IQ assessments were done by PhD-level psychologists, and the
remainder was completed by a masters-level licensed clinician or
masters-level examiners who had been trained psychometrically
and monitored throughout the trial by a licensed PhD-level clinical
psychologist.
The trial ran in two phases. Phase 1 was a 16-week, randomized,
double-blind, placebo-controlled trial testing the efficacy and
safety of a liquid formulation of metformin (Riomet) in children
and adolescents with ASD. Age was balanced across the two
treatments (placebo vs. metformin), precluding any confounding
between age and treatment effect. Phase 2 was a 16-week, open-
label extension with all participants taking metformin (total study
duration, 32 weeks). Children and adolescents were eligible if they
met the following criteria: (a) age was between 6 and 17 years, 4
months inclusive; (b) had a diagnosis of ASD (i.e., autistic disorder,
pervasive developmental disorder not otherwise specified [PDD-
NOS], or Asperger’s disorder) based upon the DSM-IV-TR clinical
interview (American Psychiatric Association 2000) and supported
by the Autism Diagnostic Observation Schedule (ADOS) (Lord
et al. 2000) or ADOS-2 (Lord et al. 2012), as appropriate; (c) taking
a stable dose of an atypical antipsychotic for a minimum of 1 month
with no planned changes; and (d) had a documented ‡7% increase
in body mass index (BMI) since starting the atypical antipsychotic
(within past 12 months) or, if BMI ‡85th percentile, a greater than
5% body weight increase per year since starting the medication, as
documented by previous weight records. All medications other than
metformin were held at constant doses.
Metformin was dispensed in a liquid formulation of 100mg/mL,
with placebo matching the appearance, smell, and taste of the
metformin. For 6–9 year olds, initial dosing began with 250mg at
the evening meal and remained consistent for 1 week. During week
2, the dosage increased by another 250mg at breakfast. At the week
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2 visit, if the previous dosage was well tolerated, it was increased
to 500mg twice daily. For 10–17 year olds, the initial dosing be-
gan following a similar schedule, but at the week 4 visit, if well
tolerated, the dosage was increased to 850mg, twice daily. Study
physicians could decrease the prescribed dosage in multiples of
50mg if participants experienced adverse events (AEs). Once AEs
resolved, participants could be rechallenged with higher dosages in
multiples of 50mg units.
For participants 6–9 years, the mean final dosage of both met-
formin and placebo was 1000mg/day (SD = 0.0) (all doses at
maximum). For participants 10–17 years of age, the mean final
dosage of metformin was 1622mg/day (– 226mg/day), and the
final dose of placebo was 1644mg/day (–284). During the open-
label extension, the mean final dosage of metformin was 900mg/
day (– 224mg/day) for younger participants and 1578mg/day
(– 339mg/day) for older participants.
Cognitive measures
Neuropsychological Assessment 2nd Edition Memory for
Designs. The Neuropsychological Assessment 2nd Edition
(NEPSY–II) is a valid and reliable assessment of children and
adolescents, for ages 3 through 16 years, on six neuropsychological
domains (Korkman et al. 2007; Davis and Matthews 2010). The
Memory for Designs (MD) subtest was developed to assess spatial
and content memory for novel visual forms. For the current study,
the starting point and level of difficulty were based on matching
each child’s mental age to the chronological age equivalents out-
lined in the NEPSY–II manual. Participants were shown a page
from a stimulus book, which included between 4 and 10 geometric
forms in various locations on a grid. After allowing 10 seconds of
viewing the geometric forms and their locations, the examiner
turned the page over and gave the design cards to the participants.
The examiner then asked participants to select the matching designs
from the cards and place them on a blank grid in the same location
as previously shown. Four trials of the same task using different
stimuli were completed.
The total number of stimulus forms correctly selected over
the four trials provided a raw Content Score (range 0–40 for ages
3 through 4 years; range 0–60 for ages 5 through 16 years) to assess
immediate recall of the designs shown in each trial. The total number
of stimulus locations correctly selected over the four trials provided a
raw Spatial Score (range 0–20 for ages 3 through 4 years; range 0–30
for ages 5 through 16 years) to assess immediate recall of locations
shown in each trial. A Bonus Score was assigned if the participant
responded correctly to both the content and the spatial elements for a
given trial. The MD Total Score is the sum of the Content, Spatial,
and Bonus Scores (range 0–100 for ages 3 through 4 years; range 0–
150 for ages 5 through 16 years).
NEPSY–II MD Delayed. The MD Delayed subtest was de-
veloped to assess long-term spatial memory in children and ado-
lescents 5 through 16 years of age. Fifteen to 25 minutes following
the administration of the MD task, the child was shown an empty
grid and asked to remember the final trial of the MD task. The child
was asked to choose the cards and place them on the grid where he
or she initially saw them.
To be administered theMD andMDDelayed subtests, participants
must have had a mental age of at least 36 months. To be scored,
participants must have begun the subtest at trial 1, regardless of
chronological age. Because several participants had mental ages be-
low 36 months, they were not administered the NEPSY–II test.
Standard scores were not available for some study participants whose
ages exceeded 16 years (i.e., theNEPSY–II standard scores only cover
3–16 year olds). Therefore, we analyzed raw scores for all variables on
this test. In all cases, higher scores reflected better performance.
We chose the NEPSY–II MD as ideal for this study for several
reasons. First, it measures both recognition for two-dimensional
designs and recall for spatial location, sampling both short-term
and long-term spatial memory. As such, the NEPSY–II is one of
very few neuropsychological batteries developed for children
(Brooks et al. 2010), which samples these variables of interest.
Second, it is suited for a relatively broad age range (3–16 years),
making it suitable for our participants, many of whom had intel-
lectual disability. Third, the NEPSY–II MD subtest is sufficiently
brief that it could be managed by most of our study participants,
many of whom had significant attentional and distractibility issues.
Finally, children with autistic disorder and Asperger’s disorder
were among the clinical groups included during development of the
NEPSY–II, indicating that such children can perform the battery.
The Modified California Verbal Learning Test for Chil-
dren. The Modified California Verbal Learning Test for Chil-
dren (MCVLT-C) (Pandina et al. 2007; Aman et al. 2008) is a
modified and simplified version of the California Verbal Learning
Test for Children (CVLT-C) (Delis et al. 1994). The MCVLT-C
assesses young people’s verbal memory ability over brief and in-
termediate intervals of time. Instead of the standard list of 15 nouns
administered in the CVLT-C, participants in this study were ad-
ministered a modified list of 10 common nouns on 5 separate
learning trials. The participants were asked to recall the words in
any order after each trial (measuring Immediate Free Recall). Once
the Trial 5 responses were recorded, participants performed the
NEPSY–II, described above, which prevented participants from
rehearsing the original verbal learning list. Following this, partic-
ipants were asked to recall as many of the words as possible (Long
Delay, Free Recall variable). Finally, a Recognition Trial was ad-
ministered to the participants, in which the 10 previously presented
and 10 new words were used. Participants then had to determine
whether they had heard the word before the recognition trial by
indicating ‘‘yes’’ or ‘‘no’’ to the examiner.
The MCVLT-C has a provision for participants who struggle with
learning the nouns in the short delay, free recall segment. If recall
was £4 correct over the first two trials, the examiner simplified the
task by using a flip chart to show drawings of the nouns as they were
read aloud. Prior testing has shown that this visual aid enhances
participants’ ability to perform the task. Such participants were then
administered all five trials with the supplementary pictures.
Three outcome variables were derived from the MVLT–C: (a)
total number of nouns recalled correctly over the five learning trials
(possible score: 0–50), (b) long delay, free recall (possible score:
0–10), and (c) number of words correctly recognized + number of
words correctly rejected (possible score: 0–20). Although the
MCVLT-C does not assess spatial memory, we included it for three
reasons. First, verbal memory is of central and undeniable impor-
tance in everyday functioning in children. Second, we knew from
previous experience (Aman et al. 2009) that youth with ASD are
able to perform the task. Third, our previous trial showed that the
MCVLT-C was sensitive to drug intervention (Aman et al. 2008).
Statistical analyses
A total sample size of 60 participants was planned for power to
detect effects of metformin on BMI z-score. For this analysis of
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cognitive effects, only 51 participants completed 1 or more usable
memory tests on at least 1 session. Before data analysis, 2 authors
(M.G.A.; J.A.H.) reviewed the raw data while blind to participant
identity (ID) and treatment assignment. Based on within-participant
variability or unacceptably low scores, we excluded data that re-
flected a lack of mastery or loss of mastery over the task. Depending
on the variable, 7–28 sessions were excluded from theMCVLT data
(mostly from the recognition trials). One to two sessions were re-
moved from the NEPSY scores. Another participant was excluded
because he was administered tasks from the wrong stratum for his
mental age, but his MCVLT data were valid, still leaving 51 par-
ticipants in all.
Effects of metformin on cognitive outcomes were estimated
from shared-baseline, random-slope, linear mixed models with
fixed effects of age stratum (3–4 vs. 5–16 years) · visit (categorical:
baseline, week 16, andweek 32) and stratum· treatment·postbaseline
visit interaction, and random participant-specific intercepts and
slopes with unstructured covariance. For NEPSY–II scales, the
covariance structure was allowed to vary across test versions for
the two age strata. Our original study (Anagnostou et al. 2016)
indicated that the two drug groups differed in IQ (higher for the
placebo group), and this difference approached significance for
the 51 participants in this study ( p = 0.10). Therefore, our linear
mixed models also contained fixed effects for IQ and IQ · visit
(categorical) to control for possible chance confounding from
baseline IQ on cognitive outcome measures.
The mean model was unstructured in time, whereas the covari-
ance model assumed participant-specific linear deviations from the
estimated means. The shared-baseline assumption, enforced by
omitting a treatment main-effect term, reflected the true state of the
population before randomization and adjusted for chance differ-
ences at baseline (Liang and Zeger 2000). Effects of treatment
assignment on 16 and 32-week change were estimated by linear
contrasts of the baseline and 16 and 32-week least-square means
using the observed stratum frequencies. Effect sizes (ESs) for
treatment differences were calculated relative to the pooled stan-
dard deviation for 16- or 32-week change for each measure among
completers. Cognitive endpoints were tested at two-tailed a= 0.05,
without adjustment for multiple comparisons.
In response to reviewer enquiries, we also analyzed to determine
whether certain subject or treatment variables influenced outcome.
These variables included age, severity of ASD, type of antipsy-
chotic taken (risperidone vs. other), presence or not of central
nervous system stimulant cotherapy, and number of co-occurring
medications. In general, these analyses were negative. They are
available on-line as Supplementary Data (Supplementary Data are
available online at www.liebertpub.com/cap).
Results
Participants
Whereas 60 participants were enrolled in the full trial to as-
sess safety and effects on weight, only 51 participants successfully
completed 1 or more of the memory tests on at least 1 session. Age
ranged from 7.2 to 17.4 years, with a mean of 12.6 and 12.8 years in
the placebo and metformin groups, respectively. The large major-
ity of participants were Caucasian and non-Hispanic. As shown
in Table 1, most participants had autistic disorder, with sizeable
subgroups diagnosed with Asperger’s disorder (29%) or PDD-NOS
(17%). In general, the parents/caregivers were well educated, with
59% having a college degree or higher. All participants were taking
one or more psychotropic drugs in addition to atypical antipsy-
chotics, with a mode of two psychotropic drugs in addition to the
antipsychotics (see Anagnostou et al. 2016, eTable 4, Supplement 2).
Table 1. Demographic Features of Study Participants
Variable Level Placebo Metformin p
Age (years) Mean (SD, n) 12.6 (2.7, 30) 12.8 (3.02, 21) 0.879
Gender Female, % (n) 26.7 (8) 28.6 (6) 0.881
Male, % (n) 73.3 (22) 71.4 (15)
IQ Mean (SD, n) 84.1 (20.3, 30) 75.3 (23.3, 18) 0.175
Race Asian American, % (n) 6.7 (2) 4.8 (1) 1.000
Black or African American, % (n) 3.3 (1) 4.8 (1)
Caucasian/White, % (n) 86.7 (26) 85.7 (18)
Other/Multiracial, % (n) 3.3 (1) 4.8 (1)
Ethnicity Hispanic, % (n) 6.9 (2) 0.0 (0) 0.503
non-Hispanic, % (n) 93.1 (27) 100 (21)
ASD diagnosis Autistic disorder, % (n) 53.3 (16) 52.4 (11) 0.175
PDD/NOS, % (n) 10.0 (3) 28.6 (6)
Asperger’s disorder, % (n) 36.7 (11) 19.0% (4)
Primary caregiver education level College or less, % (n) 40.0 (12) 42.9 (9) 0.133
College graduate, % (n) 46.7 (14) 23.8 (5)
Graduate degree, % (n) 13.3 (4) 33.3 (7)
Annual household income Under $50,000, % (n) 41.4 (12) 28.6 (6) 0.224
$50,000–$99,999, % (n) 24.1 (7) 47.6 (10)
$100,000 and over, % (n) 34.5 (10) 23.8 (5)
Additional psychotropic medications 1 Additional, % (n) 20.0 (6) 9.5 (2) 0.256
2 Additional, % (n) 23.3 (7) 52.4 (11)
3 Additional, % (n) 30.0 (9) 14.3 (3)
4 Additional, % (n) 16.7 (5) 19.0 (4)
5 Additional, % (n) 10.0 (3) 4.8% (1)
BMI (z-score) Mean (SD, n) 2.13 (0.38, 30) 1.94 (0.48, 21) 0.113
SD, standard deviation; n, sample size; PDD-NOS, pervasive developmental disorder not otherwise specified; ASD, autism spectrum disorder; BMI,
body mass index; IQ, intelligence quotient.
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The participants from both groups had BMIs two standard
deviations or more above normative means. Mean final dosage
of metformin at the end of Phase 2 did not differ between the
randomized treatment groups by t-tests ( p= 0.61 for younger,
p > 0.99 for older participants). Detailed comparisons of the
placebo and metformin groups appear in Table 1.
Cognitive outcomes, Phase 1
The results for placebo versus metformin changes for the first 16
weeks of treatment appear in themiddle panel of Table 2. Estimated
treatment differences during Phase 1 ranged from -7.4 to 4.3.
Negative estimates reflect less improvement over Phase 1 for the
metformin group than for the placebo group; positive estimates
indicate greater gains for metformin. Estimates for Phase 1 sug-
gested greater improvement among placebo participants for five of
nine measures (counter to the direction that we hypothesized).
However, of the five measures, where placebo participants showed
greater improvement, only one score showed a significant differ-
ence ( p= 0.042). ESs ranged from 0.08 to 0.51. None of the
MCVT-C comparisons approached significance.
Cognitive outcomes, for whole trial (P–M vs. M–M
comparisons, across all 32 weeks)
The right-most panel of Table 2 shows the analysis for all 32
weeks of the trial. In this analysis, we asked the question of whether
the group receiving placebo in Phase 1 showed ‘‘catch-up’’ after 16
weeks of metformin treatment. No measures differed between the
randomized treatment groups at the conclusion of Phase 2, after 32
weeks of treatment, including 16 weeks of open-label metformin
use in both arms ( p = 0.097–0.976).
We also analyzed results for the P–M (started placebo, switched
to metformin) group and M–M (started metformin, maintained on
metformin) (data not shown, for brevity). One of the nine measures
did show greater improvement during Phase 2 among participants
in the M–M group: MD Spatial Scores ( p= 0.002). For MD Spatial
Scores in Phase 2, the M–M group had a 2.79 point improvement in
scores, whereas the P–M group had a -0.62 point change (deteri-
oration) in scores. This indicates that participants performed better
when medication condition was held constant for the metformin
condition (i.e., M–M) in comparison to the placebo–metformin
condition.
Summary figures
We selected two figures to show the most important variables
from the NEPSY–II and MCVLT-C tasks. Figure 1 shows the re-
sults for all 32 weeks for MD Total Score; Figure 2 shows the
results for MCVLT-C Short Delay, Recall Score. The MD Total
Score revealed nonsignificantly worse performance for the met-
formin condition relative to placebo over the first 16 weeks. This
was followed by a slight but not significant improvement of the
M–M condition over the P–M condition at week 32. Figure 2 shows
nominally better performance for the placebo condition during the
first 16 weeks, followed by an essentially parallel performance for
P–M and M–M conditions from week 16–32 in the MCVLT-C
Short Delay, Recall task. The remaining comparisons are shown in
the Supplementary Data. Inspection of the figures for all nine
variables suggests to us that there was no consistent difference in
performance between groups. Performance was occasionally de-
pressed for the metformin group for the first 16 weeks (e.g., for MD
Spatial Score), only to surpass the P–M condition in the second
phase (weeks 16–32). The remaining figures are available on line as
supplemental material (Supplementary Figs. 1–7). Given a total of
18 statistical comparisons, we would expect about one ‘‘signifi-
cant’’ finding on the basis of chance alone. Whereas, Bonferroni
correction for multiple comparisons would require a p£ 0.003,
none of our comparisons met this criterion in our primary analyses.
Table 2. Effects of Metformin vs. Placebo (Panel 2) and Effect of Time
and Metformin (Panel 3) on Memory Performance
Variable n
PBO Phase 1 vs. Met Phase 1 Baseline to week 32
PBO-Ph1 Met Ph1 Estim. p E.S. PBO-Met Met-Met Estim. p E.S.
NEPSY MD
MD Content Score (0–60)a 45 2.126 2.718 0.593 0.732 0.084 3.447 6.100 2.653 0.206 0.388
MD Spatial Score (0–30)b 45 1.210 -0.769 -1.979 0.042 0.464 0.589 2.017 1.428 0.228 0.354
MD Total Score (0–150)c 45 12.727 5.370 -7.357 0.208 0.357 15.269 20.280 5.011 0.491 0.215
MDD Content Score (0–20)d 37 1.108 1.378 0.270 0.718 0.129 1.159 0.361 -0.799 0.494 0.225
MDD Spatial Scores (0–10)e 37 0.988 0.405 -0.583 0.107 0.451 0.380 0.395 0.015 0.976 0.011
MDD Total Score (0–50)f 37 6.089 2.593 -3.497 0.182 0.514 3.622 1.761 -1.861 0.592 0.185
Modified California Verbal Learning Test-C
Short Delay Recall Score (0–50) 48 1.342 0.065 -1.278 0.524 0.186 4.666 3.267 -1.399 0.423 0.227
Long Delay Recall Score (0–10) 48 -0.063 0.303 0.366 0.560 0.181 0.488 1.358 0.871 0.097 0.476
Recognitions and Rejections Score (0–20) 44 0.157 4.421 4.265 0.127 0.340 4.027 4.789 0.762 0.797 0.077
In all cases, ‘‘Estim.’’ (estimate) refers to the estimation of differences in changes for placebo and/or metformin. Block 1(PBO Phase 1 vs. Met Phase
1) answers the question of whether the initial placebo-controlled phase showed an effect of metformin on cognition. Block 2 (Baseline to Week 32)
answers the question of whether the placebo group would show ‘‘catch-up’’ when treated with metformin in Phase 2. Minus (-) estimation figures indicate
higher performance for the placebo group over metformin (in Phase 1) and greater improvement for the M–M group than for P–M group in Phase 2.
NEPSY test difficulty levels were based on participants’ MAs.
a3–4 years MA, 0–40; 5–6 years MA, 0–48; 7–16 years MA, 0–60.
b3–4 years MA, 0–20; 5–6 years MA, 0–24; 7–16 years MA, 0–30.
c3–4 years MA, 0–100; 5–6 years MA, 0–120; 7–16 years MA, 0–150.
d3–4 years MA, N/A; 5–6 years MA, 0–16; 7–16 years MA, 0–20.
e3–4 years MA, N/A; 5–6 years MA, 0–8; 7–16 years MA, 0–10.
f3–4 years MA, N/A; 5–6 years MA, 0–40; 7–16 years MA, 0–50.
PBO, placebo; Met, metformin; MD, Memory for Designs; MDD, Memory for Designs Delayed; MAs, mental ages; E.S., effect size.
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Discussion
Despite human and rodent data suggesting that metformin
treatment could potentially enhance memory (especially spatial
memory), we saw little evidence of improvement or worsening.
Visual inspection of memory performance on all nine variables of
interest from the NEPSY–II and MVLT-C revealed no consistent
pattern of treatment effect. ASD is a neurodevelopmental disorder
often accompanied by intellectual disability and other learning
difficulties; therefore it is important that we also saw little inter-
ference with memory variables either.
As all participants were being treated with atypical antipsychotic
medications, it is probable that severe irritability and/or disruptive
behavior were ongoing concerns for these youth. It is important
to recognize that such children can be exceptionally difficult to
assess for cognitive effects of pharmacological interventions.
Comorbidities, such as attention-deficit/hyperactivity disorder,
are often present in addition to the disruptive behaviors that led to
prescribing of the atypical antipsychotic medication. Indeed, most
participants were taking two additional psychotropic medications
other than the atypical antipsychotic and metformin. Troost et al.
(2006) compared effects of risperidone and placebo in children
with predominantly PDD-NOS treated for irritability and found
that only about 50% of the sample could perform two attentional
tasks. Likewise, Aman et al. (2008) reported that only 35% of 101
youth with autistic disorder could comply with any test procedures
when assessed on a cognitive battery that incorporated five tasks.
It is worth noting that researchers in Toronto have preliminary data
suggesting that female rodents, but not males, were able to recover
spatial working memory in an injury model when treated with met-
formin (Rebecca Ruddy, unpublished observations, University of
Toronto, March, 2017). Thus, given that our data were derived from
only 14 female participants (27%) out of 51, they might not be ca-
pable of detecting any such sex-specific effect, if one exists in human
FIG. 1. Memory for designs total score. Weeks 0–16 compared placebo and metformin treatment. During weeks 17–32, open-label
metformin was given to all participants. Possible scores ranged from 0 to 150, with higher scores reflecting better performance.
FIG. 2. Short delay recall score on the MCVLT-C task. Weeks 0–16 compared placebo and metformin treatment. During weeks 17–
32, open-label metformin was given to all participants. Possible scores ranged from 0 to 50, with higher scores reflecting better
performance. MCVLT-C, Modified California Verbal Learning Test for Children.
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beings. Therefore, one should not conclude from our data that met-
formin has no cognitive effects. Instead, there appears to be no dis-
cernable pattern, thus far, in children withASD and irritable behavior.
Additional studies of this type, both with children having ASD
(ideally with enhanced female representation) and with totally dif-
ferent clinical populations, are certainly warranted.
Finally, we note that the cognitive benefit reported from previous
studies in our Introduction was in the context of brain dysfunction
from T2D, high blood sugar, high insulin, or trauma. It is possible
that metformin offers cognitive benefit, but only in circumstances
of metabolic brain stress. Alternatively, it is also possible that it
may only work through the mechanism of normalizing blood sugar
and insulin receptor sensitivity.
Limitations
Limitations of this study include the small sample, with 51 youth
able to provide any data. Additionally, a substantial portion of the
MCVLT-C data was excluded because of lack of mastery over the
task. All participants were receiving an atypical antipsychotic and at
least one additional psychotropic medication, and 84% were receiv-
ing at least two other psychotropicmedications.Hence, the possibility
of other drugs interacting with metformin cannot be discounted. Fi-
nally, based on limited data relating to cognitive effects with met-
formin, we only assessed these youth for drug effects on memory
functions; it is possible that metformin may affect other cognitive
domains, such as aspects of attention or executive functioning.
Conclusion
In 51 youth with ASD participating in a trial of metformin for
weight reduction, we observed no clear-cut effects of treatment on
spatial or verbal memory. However, evaluating cognitive func-
tioning in children with ASD and irritable behavior presented
numerous challenges. The matter deserves more study.
Clinical Significance
Despite some evidence to the contrary from studies of humans
and animals, our data offer little reason to believe that metformin
treatment affects memory performance in children and adolescents
with ASD.
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